Similar conceptual approaches, have involved fusing the B7-H6 ectodomain (with the aim of engaging NKp30 on NK cells) to either an anti-Human Epidermal Growth factor 2 (HER2) scFv to enhance NK cell killing of HER2+ breast cancers (191) or an anti-CD20 scFv to target lymphomas (192, 193). This evidence concerns the gene NCR3 and lymphoma.